PT  - JOURNAL ARTICLE
AU  - Vetter, Valentin Max
AU  - Kalies, Christian Humberto
AU  - Sommerer, Yasmine
AU  - Spira, Dominik
AU  - Drewelies, Johanna
AU  - Regitz-Zagrosek, Vera
AU  - Bertram, Lars
AU  - Gerstorf, Denis
AU  - Demuth, Ilja
TI  - Relationship between five Epigenetic Clocks, Telomere Length and Functional Capacity assessed in Older Adults: Cross-sectional and Longitudinal Analyses
AID  - 10.1101/2021.10.05.21264547
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.05.21264547
4099  - http://medrxiv.org/content/early/2021/10/07/2021.10.05.21264547.short
4100  - http://medrxiv.org/content/early/2021/10/07/2021.10.05.21264547.full
AB  - DNA methylation age acceleration (DNAmAA, derived from an epigenetic clock) and relative leukocyte telomere length (rLTL) are widely accepted biomarkers of aging. Nevertheless, it is still unclear which aspects of aging they represent best. Here we evaluated longitudinal associations between baseline rLTL and DNAmAA (estimated with 7-CpG clock) and functional assessments covering different domains of aging. Additionally, we made use of cross-sectional data on these assessments and examined their association with DNAmAA estimated by five different DNAm age measures.Two-wave longitudinal data was available for 1,083 participants of the Berlin Aging Study II (BASE-II) who were re-examined on average 7.4 years after baseline as part of the GendAge study. Functional outcomes were assessed with Fried’s frailty score, Tinetti mobility test, falls in the past 12 months (yes/no), Finger-floor distance, Mini Mental State Examination (MMSE), Center for Epidemiologic Studies Depression Scale (CES-D), Activities of Daily Living (ADL), Instrumented ADL (IADL) and Mini Nutritional Assessment (MNA).Overall, we found no evidence for an association between the molecular biomarkers measured at baseline, rLTL and DNAmAA (7-CpG clock), and functional assessments assessed at follow-up. Similarly, a cross-sectional analyses of follow-up data did also not show evidence for associations of the various DNAmAA measures (7-CpG clock, Horvath’s clock, Hannum’s clock PhenoAge, and GrimAge) with functional assessments.In conclusion, neither rLTL nor 7-CpG DNAmAA were able to predict impairment in the analyzed assessments over a ∼7 year time-course. Similarly, DNAmAA as estimated by five epigenetic clocks was not a good cross-sectional marker of health deterioration either.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants of the Deutsche Forschungsgemeinschaft (grant number DE 842/7-1 to ID), the ERC (as part of the Lifebrain project to LB), and the Cure Alzheimer Fund (as part of the CIRCUITS consortium to LB). This article uses data from the Berlin Aging Study II (BASE-II) and the GendAge study which were supported by the German Federal Ministry of Education and Research under grant numbers #01UW0808; #16SV5536K, #16SV5537, #16SV5538, #16SV5837, #01GL1716A and #01GL1716B. We thank all probands of the BASE-II/GendAge study for their participation in this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The medical assessments at baseline and follow-up were conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Charite - Universitaetsmedizin Berlin (approval numbers EA2/029/09 and EA2/144/16).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request. Interested investigators are invited to contact the study coordinating PI Ilja Demuth at ilja.demuth{at}charite.de to obtain additional information about the GendAge study and the data-sharing application form.